Author

S. S. McDade

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 8 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 8 Organism:human· 8 Assay:bulk RNA-seq· 6 Research Focus:drug response / drug discovery· 4 Research Focus:cancer & tumor microenvironment· 3 Approach:statistical model· 3 Research Focus:cell type annotation· 2 Research Focus:chromatin & epigenetic regulation· 2

Frequent Co-Authors

I. Mills· 3 shared A. Pickard· 2 shared C. Latimer· 2 shared C. McCann· 2 shared D. B. Longley· 2 shared D. Mukherjee· 2 shared E. M. Kerr· 2 shared F. Falcone· 2 shared

Activity by Year

2017-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

I. Mills

Mutual co-authors in cluster

Author profile →

9 papers

Recent·Most cited

Ribosome Quality Control Mechanism Mitigates the Cytotoxic Impacts of Ribosome Collisions Induced by 5-Fluorouracil

S. Chatterjee, P. Naeli, N. Simms, A. Garzia, A. Hackett, K. Coyle, P. Harris Snell, T. McGirr, T. N. Sawant, K. Dang, Z. V. Stoichkova, T. Alain, T. Tuschl, S. S. McDade, D. Longley, , S. M. Jafarnejad

This study shows that 5-Fluorouracil induces ribosome collisions, which are mitigated by the RQC mechanism through mTOR-dependent regulation of RQC factors.

bioRxiv · Dec 26, 2023Cell Biology

IRF7 impacts on prostate cancer cell survival in response to radiation

A. Pickard, F. Amoroso, K. McCulloch, A. Erickson, A. Sachdeva, R. Steele, D. Mukherjee, M. Dellett, J. McComb, L. McCaffrey, C. Hart, M. Brown, S. S. McDade, D. Waugh, N. Clarke, , I. Mills

This study investigates how IRF7 influences prostate cancer cell survival after radiation and identifies therapeutic vulnerabilities linked to IRF7 expression.

bioRxiv · Sep 23, 2022 · PreprintCancer Biology

Bcl-xL is a key mediator of apoptosis following KRASG12C inhibition in KRASG12C mutant colorectal cancer.

H. Khawaja, R. Briggs, C. Latimer, M. Rassel, D. Griffin, L. Hanson, A. Bardelli, F. Di Nicolantonio, S. S. McDade, C. J. Scott, S. Lambe, M. Maurya, A. U. Lindner, J. H. M. Prehn, J. Sousa, , S. Van Schaeybroeck

This study identifies Bcl-xL as a mediator of resistance to KRASG12C inhibitors in colorectal cancer and shows that combining Bcl-xL inhibition with KRASG12C inhibition enhances apoptosis and reduces tumor growth.

bioRxiv · May 10, 2022Cancer Biology

VPRBP functions downstream of the androgen receptor and OGT to restrict p53 activation in prostate cancer

N. Poulose, A. Polonski, N. Forsythe, G. Gregg, S. Maguire, M. Fuchs, S. Minner, S. S. McDade, I. Mills

This study identifies VPRBP as a co-regulator of the androgen receptor and OGT that suppresses p53 activation in prostate cancer, linking its expression to poor clinical outcomes.

bioRxiv · Feb 28, 2021Cancer Biology

Clinical positioning of the IAP antagonist tolinapant (ASTX660) in colorectal cancer

D. B. Longley, N. T. Crawford, K. J. Stott, T. Sessler, C. McCann, W. McDaid, C. Latimer, J. Fox, J. M. Munck, T. Smyth, A. Shah, V. Martins, M. Lawler, P. D. Dunne, E. M. Kerr, , V. M. Coyle

This study shows tolinapant, an IAP inhibitor, enhances chemotherapy-induced apoptosis in colorectal cancer by modulating FLIP and HDACs, suggesting its clinical use in poor prognosis MSS CRC with elevated cIAP1/2.

bioRxiv · Nov 20, 2020Cancer Biology

Development of a novel allograft model of prostate cancer: a new tool to inform clinical translation

C. Haughey, D. Mukherjee, R. Steele, A. Popple, L. Dura-Perez, A. Pickard, S. Jain, P. Mullan, R. Williams, P. Oliveira, N. Buckley, J. Honeychurch, S. S. McDade, T. Illidge, I. Mills, S. Eddie

This paper develops a novel allograft model of high-risk prostate cancer that mimics human disease features and responds to radiotherapy.

bioRxiv · Feb 16, 2020 · PreprintCancer Biology

FLIP(L) determines p53 induced life or death

A. Lees, A. J. McIntyre, F. Falcone, N. T. Crawford, C. McCann, G. P. Quinn, J. Z. Roberts, T. Sessler, P. F. Gallagher, K. McAllister, K. McLaughlin, W. L. Allen, C. Holohan, L. J. Egan, A. E. Ryan, , S. S. McDade

This study identifies FLIP(L) as a p53 target that determines cell fate by promoting cell cycle arrest and inhibiting apoptosis.

bioRxiv · Nov 28, 2019 · PreprintCancer Biology

Chronic loss of STAG2 leads to altered chromatin structure contributing to de-regulated transcription in AML

J. S. Smitth, S. G. Craig, F. G. Liberante, K. M. Lappin, C. M. Crean, S. S. McDade, A. Thompson, K. Mills, K. I. Savage

This study shows that chronic STAG2 loss alters chromatin structure and deregulates transcription in AML, affecting HOXA and MAPK pathways.

bioRxiv · Nov 26, 2019Cancer Biology

Transcription factor activities enhance markers of drug response in cancer

L. Garcia-Alonso, F. Iorio, A. Matchan, N. Fonseca, P. Jaaks, F. Falcone, G. Bignell, S. S. McDade, M. J. Garnett, J. Saez-Rodriguez

The paper uses computational methods to infer transcription factor activities from RNA-seq data and shows their utility as markers for drug response in cancer.

bioRxiv · Apr 21, 2017Cancer Biology